Peptron, Inc.

KOSDAQ 087010.KQ

Peptron, Inc. Cash and Short-Term Investments for the year ending December 31, 2023: USD 3.83 M

Peptron, Inc. Cash and Short-Term Investments is USD 3.83 M for the year ending December 31, 2023, a -71.91% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.
  • Peptron, Inc. Cash and Short-Term Investments for the year ending December 31, 2022 was USD 13.62 M, a -46.17% change year over year.
  • Peptron, Inc. Cash and Short-Term Investments for the year ending December 31, 2021 was USD 25.31 M, a -60.95% change year over year.
  • Peptron, Inc. Cash and Short-Term Investments for the year ending December 31, 2020 was USD 64.81 M, a 327.83% change year over year.
  • Peptron, Inc. Cash and Short-Term Investments for the year ending December 31, 2019 was USD 15.15 M, a -45.42% change year over year.
Key data
Date Cash and Short-Term Investments Receivables Inventory Goodwill
Market news
KOSDAQ: 087010.KQ

Peptron, Inc.

CEO Mr. Ho-Il Choi
IPO Date July 22, 2015
Location South Korea
Headquarters 37-24, Yuseong-daero 1628 beon-gil
Employees 94
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Peptron, Inc. engages in the development of peptide-based medicines to treat chronic diseases. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, and puberty; SR-Octreotide (PT201) for the treatment of acromegaly; SR-Exenatide (PT302) to treat type 2 diabetes; and SR-Exenatide (PT320) for Parkinson's and Alzheimer's disease. Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea.

StockViz Staff

January 15, 2025

Any question? Send us an email